Biocon, Quark In Pact To Develop siRNA Drugs For Eye Diseases
This article was originally published in PharmAsia News
Executive Summary
Biocon and Quark Pharmaceuticals have signed a collaboration agreement to develop eye treatments based on small interfering RNA technology.